Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment
Related Experiment Video
Updated: Apr 3, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Besu F Teshome1,2,3, Grace C Lee4,5, Kelly R Reveles6,7
1St. Louis College of Pharmacy, St. Louis, MO, USA. besu.teshome@stlcop.edu.
Background:
Community-onset (CO) methicillin-resistant Staphylococcus aureus (MRSA) pneumonia is an evolving problem, and there is a great need for a reliable method to assess MRSA risk at hospital admission. A new MRSA prediction score classifies CO-pneumonia patients into low, medium, and high-risk groups based on objective criteria available at baseline. Our objective was to assess the effect of initial MRSA therapy on mortality in these three risk groups.
Methods:
We conducted a retrospective cohort study using data from the Veterans Health Administration (VHA). Patients were included if they were hospitalized with pneumonia and received antibiotics within the first 48 h of admission. They were stratified into MRSA therapy and no MRSA therapy treatment arms based on antibiotics received in the first 48 h. Multivariable logistic regression was used to adjust for potential confounders.
Results:
A total of 80,330 patients met inclusion criteria, of which 36% received MRSA therapy and 64% did not receive MRSA therapy. The majority of patients were classified as either low (51%) or medium (47%) risk, with only 2% classified as high-risk. Multivariable logistic regression analysis demonstrated that initial MRSA therapy was associated with a lower 30-day mortality in the high-risk group (adjusted odds ratio 0.57; 95% confidence interval 0.42-0.77). Initial MRSA therapy was not beneficial in the low or medium-risk groups.
Conclusions:
This study demonstrated improved survival with initial MRSA therapy in high-risk CO-pneumonia patients. The MRSA risk score might help spare MRSA therapy for only those patients who are likely to benefit.
Insights
Initial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia therapy improved survival in high-risk patients. A new MRSA risk score can guide targeted MRSA treatment, sparing unnecessary antibiotics in low-risk individuals.
Area of Science:
- Infectious Diseases
- Clinical Medicine
- Epidemiology
Background:
- Community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) pneumonia presents a growing clinical challenge.
- A validated MRSA prediction score stratifies patients into low, medium, and high-risk categories upon hospital admission.
- Assessing the impact of early MRSA-targeted antibiotic therapy on mortality is crucial for optimizing patient outcomes.
Purpose of the Study:
- To evaluate the association between initial MRSA therapy and 30-day mortality in community-onset pneumonia patients.
- To determine if the benefits of MRSA therapy differ across risk strata defined by a novel prediction score.
Main Methods:
- A retrospective cohort study utilized data from the Veterans Health Administration (VHA).
- Patients hospitalized with pneumonia receiving antibiotics within 48 hours were analyzed.
- Multivariable logistic regression adjusted for confounders to compare outcomes between MRSA and non-MRSA therapy groups.
Main Results:
- Of 80,330 patients, 36% received MRSA therapy. Most patients were low (51%) or medium (47%) risk; only 2% were high-risk.
- Initial MRSA therapy was linked to significantly lower 30-day mortality in the high-risk group (aOR 0.57; 95% CI 0.42-0.77).
- No mortality benefit was observed for MRSA therapy in the low or medium-risk groups.
Conclusions:
- Early MRSA-targeted antibiotic treatment improves survival specifically in high-risk community-onset pneumonia patients.
- The MRSA risk prediction score effectively identifies patients who are most likely to benefit from MRSA therapy.
- This risk stratification may help optimize antibiotic use, reserving MRSA treatment for appropriate cases.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:29Staphylococcal Skin Infections
01:25Mechanism of Antibiotic Resistance in MRSA
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:30Pneumonia III: Complications and Assessment